Evidence map›Paper›PMID 30541027›Full record

ArticleHuman molecular genetics2019

A robust pipeline with high replication rate for detection of somatic variants in the adaptive immune system as a source of common genetic variation in autoimmune disease.

Lies Van Horebeek, Kelly Hilven, Klara Mallants, Annemarie Van Nieuwenhuijze, Tiina Kelkka, Paula Savola, Satu Mustjoki, Susan M Schlenner, Adrian Liston, Bénédicte Dubois and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Human molecular genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Copy number variations across the blood-brain barrier in multiple sclerosis.Annals of clinical and translational neurology · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Lies Van HorebeekKU Leuven, Department of Neurosciences, Laboratory for Neuroimmunology, Leuven, Belgium.
Kelly HilvenKU Leuven, Department of Neurosciences, Laboratory for Neuroimmunology, Leuven, Belgium.
Klara MallantsKU Leuven, Department of Neurosciences, Laboratory for Neuroimmunology, Leuven, Belgium.
Annemarie Van NieuwenhuijzeVIB & KU Leuven Center for Brain and Disease Research, VIB, KU Leuven, Leuven, Belgium.
Tiina KelkkaHematology Research Unit Helsinki, University of Helsinki, Department of Hematology, Helsinki University Hospital Comprehensive Cancer Centre, FIN-00290 Helsinki, Finland.
Paula SavolaHematology Research Unit Helsinki, University of Helsinki, Department of Hematology, Helsinki University Hospital Comprehensive Cancer Centre, FIN-00290 Helsinki, Finland.
Satu MustjokiHematology Research Unit Helsinki, University of Helsinki, Department of Hematology, Helsinki University Hospital Comprehensive Cancer Centre, FIN-00290 Helsinki, Finland.
Susan M SchlennerVIB & KU Leuven Center for Brain and Disease Research, VIB, KU Leuven, Leuven, Belgium.
Adrian ListonVIB & KU Leuven Center for Brain and Disease Research, VIB, KU Leuven, Leuven, Belgium.
Bénédicte DuboisKU Leuven, Department of Neurosciences, Laboratory for Neuroimmunology, Leuven, Belgium.
An GorisKU Leuven, Department of Neurosciences, Laboratory for Neuroimmunology, Leuven, Belgium.
KU Leuven · BEUniversity of Helsinki · FIVIB-KU Leuven Center for Brain & Disease Research · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of somatic variants in diseases beyond cancer is increasingly being recognized, with potential roles in autoinflammatory and autoimmune diseases. However, as mutation rates and allele fractions are lower, studies in these diseases are substantially less tolerant of false positives, and bio-informatics algorithms require high replication rates. We developed a pipeline combining two variant callers, MuTect2 and VarScan2, with technical filtering and prioritization. Our pipeline detects somatic variants with allele fractions as low as 0.5% and achieves a replication rate of >55%. Validation in an independent data set demonstrates excellent performance (sensitivity > 57%, specificity > 98%, replication rate > 80%). We applied this pipeline to the autoimmune disease multiple sclerosis (MS) as a proof-of-principle. We demonstrate that 60% of MS patients carry 2-10 exonic somatic variants in their peripheral blood T and B cells, with the vast majority (80%) occurring in T cells and variants persisting over time. Synonymous variants significantly co-occur with non-synonymous variants. Systematic characterization indicates somatic variants are enriched for being novel or very rare in public databases of germline variants and trend towards being more damaging and conserved, as reflected by higher phred-scaled combined annotation-dependent depletion (CADD) and genomic evolutionary rate profiling (GERP) scores. Our pipeline and proof-of-principle now warrant further investigation of common somatic genetic variation on top of inherited genetic variation in the context of autoimmune disease, where it may offer subtle survival advantages to immune cells and contribute to the capacity of these cells to participate in the autoimmune reaction.

Indexed as

Adaptive ImmunityAdultAlgorithmsAllelesAutoimmune DiseasesComputational BiologyDNA Mutational AnalysisFemaleGenetic VariationHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationPolymorphism, Single NucleotideReproducibility of Results

Identifiers

PMID30541027
PMCPMC6452186
OpenAlexW2912502827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.